11 articles.
[ Cancer Biomarkers & Immunotherapy Testing ]
Understand what PD-L1 IHC measures, how TPS, CPS and immune-cell scores are calculated, and why results must be interpreted by your oncology team.
Oct 24, 2026 12 min read
[ Comprehensive Genomic Profiling & NGS Testing ]
Variants, biomarkers, evidence tiers and the questions to take to your oncologist
Oct 20, 2026 8 min read
[ Comprehensive Genomic Profiling & NGS Testing ]
How the panels differ and how to read a comprehensive genomic profile
Oct 20, 2026 10 min read
[ Breast Cancer Genomic Testing & Diagnostics ]
What the tests measure and how results support treatment discussions
Oct 20, 2026 9 min read
[ Comprehensive Genomic Profiling & NGS Testing ]
What VAF measures, why percentages vary and what they cannot tell you alone
Oct 20, 2026 8 min read
[ Cancer Biomarkers & Immunotherapy Testing ]
What a fusion means, how testing finds it and why the method matters
Oct 20, 2026 8 min read
[ Breast Cancer Genomic Testing & Diagnostics ]
Luminal A, Luminal B, HER2 and Basal types—and how they differ from routine pathology labels
Oct 20, 2026 8 min read
[ Breast Cancer Genomic Testing & Diagnostics ]
Risk categories, the MammaPrint Index and what to discuss when the report arrives
Oct 20, 2026 9 min read
[ Cancer Biomarkers & Immunotherapy Testing ]
Understand MSI-high, MSI-low, MSS and dMMR, how PCR, IHC and NGS testing work, and how cancer biomarker reports are interpreted.
Oct 20, 2026 15 min read
[ Hereditary Cancer Risk & Genetic Testing ]
Understand HBOC, BRCA1/2 and other genes, inheritance, counselling, test choices and why a negative BRCA result may not exclude hereditary risk.
Oct 20, 2026 18 min read
[ Hereditary Cancer Risk & Genetic Testing ]
Understand BRCA1 and BRCA2, germline versus somatic findings, pathogenic variants, VUS results and genetic counselling in India.
Oct 20, 2026
